Results of three-dimensional conformal radiotherapy and thalidomide for advanced hepatocellular carcinoma

Japanese Journal of Clinical Oncology

Volumn 36, Issue 2, 2006, Pages 93-99

  Hsu, Wei Chung ^a   Chan, Sue Ching ^b   Ting, Lai Lei ^c   Chung, Na Na ^a   Wang, Po Ming ^a,d   Ying, K S Kung Shih ^a   Shin, Jeng Shiann ^a   Chao, Che Jen ^a   Lin, Gau De ^a  

^a CHENG CHING GENERAL HOSPITAL   (Taiwan)

^b BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d NONE   (Taiwan)

Author keywords

Conformal radiotherapy; Hepatocellular carcinoma; Thalidomide

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; THALIDOMIDE;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASCITES; CANCER SURVIVAL; COMPUTER ASSISTED RADIOTHERAPY; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG DOSE REGIMEN; DRUG RESPONSE; FACTORIAL ANALYSIS; FATIGUE; FEMALE; FEVER; GASTRITIS; HEPATOBILIARY DISEASE; HUMAN; INSOMNIA; KARNOFSKY PERFORMANCE STATUS; KIDNEY DISEASE; LEG EDEMA; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERCEPTION DISORDER; PORTAL VEIN THROMBOSIS; PRURITUS; RADIATION DOSE; RASH; SKIN MANIFESTATION; SURVIVAL RATE; THERAPY EFFECT; TUMOR VOLUME; UNIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMAGING, THREE-DIMENSIONAL; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RADIOTHERAPY, CONFORMAL; SURVIVAL ANALYSIS; SURVIVAL RATE; THALIDOMIDE; TREATMENT OUTCOME;

EID: 33645142946     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyi242     Document Type: Article

References (37)

1. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985;4:918-27.
2. Lin TY, Lee CS, Chen KM, Chen CC. Role of surgery in the treatment of primary carcinoma of the liver: A 31-year experience. Br J Surg 1987;74:839-42.
3. Di Bisceglie AM, Rustgi VK, Hoofnagle JH, Dusheiko GM, Lotze MT. NIH Conference: Hepatocellular carcinoma. Ann Intern Med 1988;108: 390-401.
4. Stuart KE, Anand AJ, Jenkins RL. Hepatocelular carcinoma in the United States. Prognostic features, treatment outcome, and survival. Cancer 1996;77:2217-22.
5. Liu CL, Fan ST. Nonresectional therapies for hepatocellular carcinoma. Am J Surg 1997;173:358-65.
6. Cheng SH, Lin YM, Chuang VP, Yang PS, Cheng JC, Huang AT, et al. A pilot study of three-dimensional conformal radiotherapy in unresectable hepatocellular carcinoma. J Gastroenterol Hepatol 1999;14: 1025-33.
7. Hsu WC, Wang PM, Ying KS, Chao CJ, Huang JC, Lin GD. Preliminary results of three-dimensional conformal radiotherapy for hepatocellular carcinoma with portal vein thrombosis. Chin J Radiol 2002;27:59-66.
8. Lawrence TS, Ten Haken RK, Kessler ML, Robertson JM, Lyman JT, Lavigne ML, et al. The use of 3-D dose volume analysis to predict radiation hepatitis. Int J Radiat Oncol Biol Phys 1992;23:781-8.
9. Dhir V, Swaroop VS, Mohandas KM, Dinshaw KA, Desai DC, Nagral A, et al. Combination chemotherapy and radiation for palliation of hepatocellular carcinoma. Am J Clinl Oncol 1992;15:304-7.
10. Robertson JM, Lawrence TS, Andrews JC, Walker, Kessler ML, Ensminger WD. Long-term results of hepatic artery fluorodeoxyuridine and conformal radiation therapy for primary hepatiobiliary cancers. Int J Radiat Oncol Biol Phys 1997;37:325-30.
11. Robertson JM, Lawrence TS, Dworzanin LM, Andrews JC, Walker S, Kessler ML, et al. Treatment of primary hepatobiliary cancer with conformal radiation therapy and regional chemotherapy. J Clin Oncol 1993;11:1286-93.
12. Wang PM, Hsu WC, Ying KS, Chen SJ, Chao CJ, Huang JC, et al. Hyperfractionated three-dimensional conformal radiotherapy for small hepatocellular carcinoma: A pilot study. Chin J Radiol 2002;27:281-7.
13. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989;339: 58-61.
14. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
15. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-71.
16. Singhal S, Mehta J. Thalidomide in cancer. Biomed Pharmacother 2002;56:4-12.
17. Stebbing J, Benson C, Eisen T, Pyle L, Smalley K, Bridle H, et al. The treatment of advanced renal cell cancer with high-dose oral thalidomide. Br J Cancer 2001;85:953-8.
18. Patt YZ, Hassan MM, Lozano RD, Zeldis JB, Schnirer I, Frome A, et al. Phase II trial of thalidomide for treatment of non-resectable hepatocellular carcinoma. Proc Am Soc Clin Oncol 2000;18:1035.
19. Hsu C, Chen CN, Chen LT, Wu CY, Yang PM, Lai MY, et al. Low-dose thalidomide treatment for advanced hepatocellular carcinoma. Oncology 2003;65:242-9.
20. Wang PM, Hsu WC, Chan SC, Chung NN, Ting LL, Ying KS, et al. Preliminary results of three-dimensional conformal radiotherapy and thalidomide for advanced hepatocellular carcinoma. Therapeut Radiol Oncol 2003;10:209-18.
21. American Joint Committee on Cancer. AJCC Cancer Staging Manual, 5th edn. Philadelphia, PA: Lippincott-Raven Publishers 1997;97-101.
22. Okuda K. Early detection of hepatocellular carcinoma. Hepatology 1986;6:729-38.
23. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. JNCI 2000;92:205-16.
24. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events. Version 3.0. National Cancer Institute. Available at URL: http://ctep.info.nih.gov
25. Stillwagon GB, Order SE, Guse C, Klein JL, Leichner PK, Leibel SA, et al. 194 hepatocellular cancers treated by radiation and chemotherapy combinations: Toxicity and response: A Radiation Therapy Oncology Group study. Int J Radiat Oncol Biol Phys 1989;17:1223-29.
26. Cheng JC, Chung VP, Cheng SH, Huang AT, Lin YM, Cheng TI, et al. Local radiotherapy with or without transcatheter arterial chemoembolization for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2000;47:435-42.
27. Seong J, Park HC, Han KH, Chon CY. Clinical results and prognostic factors in radiotherapy for unresectable hepatocellular carcinoma: A retrospective study of 158 patients. Int J Radiat Oncol Biol Phys 2003;55:329-36.
28. Johnson PJ, Williams R. Serum alpha-fetoprotein estimations and doubling time in hepatocellular carcinoma: Influence of therapy and possible value in early detection. JNCI 1980;64:1329-32.
29. Seong J, Keum KC, Han KH, Lee DY, Lee JT, Chon CY, et al. Combined transcatheter arterial chemoembolization and local radiotherapy of unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 1999;43:393-7.
30. Matsuura M, Nakajuma N, Arai K, Ito K. The usefulness of radiation therapy for hepatocellular carcinoma. Hepato-Gastroenterology 1998;45: 791-6.
31. Friedman MA, Volberding PA, Cassidy MJ, Resser KJ, Wasserman TH, Phillips TL. Therapy for hepatocellular cancer with intra-hepatic arterial adriamycin and 5-fluorouracil combined with whole-liver irradiation: A Northern California Oncology Group study. Cancer Treat Rep 1979;63:1885-8.
32. Liadó L, Virgili J, Figueras J, Valls C, Dominguez J, Rafecas A, et al. A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. Cancer 2000;88:50-7.
33. Calabrese L, Fleischer AB. Thalidomide: Current and potential clinical applications. Am J Med 2000;108:487-95.
34. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: Therapeutic implications. Blood 2002;99:4525-30.
35. Richardson P, Hideshima T, Anderson K. Thalidomide: Emerging role in cancer medicine. Annu Rev Med 2002;53:629-57.
36. Tazawa J, Maeda M, Sakai Y, Yamane M, Ohbayashi H, Kakinuma S, et al. Radiation therapy in combination with transcatheter arterial chemoembolization for hepatocellular carcinoma with extensive portal vein involvement. J Gastroenterol Hepatol 2001;16:660-5.
37. Chen CJ, Yu MW, Liaw YF. Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastroenterol Hepatol 1997;12: S297-308.